CTOs on the Move

Purdue Pharma

www.purduepharma.com

 
Purdue Pharma L.P. is a privately held pharmaceutical company founded by physicians more than 60 years ago. We are committed to advancing the care of patients with innovative, quality products that make a positive impact on healthcare — and on lives. Purdue Pharma is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The Company is engaged in the research, development, production, and marketing of prescription medicines and over-the-counter healthcare products. We are pursuing a promising pipeline of new medications through internal research & development ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.purduepharma.com
  • 201 Tresser Blvd One Stamford Forum
    Stamford, CT USA 06901
  • Phone: 203.588.8000

Executives

Name Title Contact Details

Similar Companies

Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is a clinical stage private biopharma with prodrug platforms that address opioid use disorder. Trypsin-Activated Abuse Protection (TAAP) technology forms an opioid prodrug that can only be activated through a 2-step internal digestive process, and therefore cannot be abused by chewing, snorting or IV administration.

Economist Intelligence Unit

Economist Intelligence Unit is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verge Genomics

We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.

Uromedica

Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellarity

Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.